All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC1052 | Human anti-RYR3 T cell receptor (AB10), pCDTCR1 | Human | AB10 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector | |
TCR-YC1053 | Human anti-RYR3 T cell receptor (AE7), pCDTCR1 | Human | AE7 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector | |
TCR-YC1054 | Human anti-RYR3 T cell receptor (BA1), pCDTCR1 | Human | BA1 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector | |
TCR-YC1055 | Human anti-RYR3 T cell receptor (BA4), pCDTCR1 | Human | BA4 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector | |
TCR-YC1056 | Human anti-RYR3 T cell receptor (BE1), pCDTCR1 | Human | BE1 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector | |
TCR-YC1057 | Human anti-RYR3 T cell receptor (BH11), pCDTCR1 | Human | BH11 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector | |
TCR-YC1058 | Human anti-RYR3 T cell receptor (FA1), pCDTCR1 | Human | FA1 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector | |
TCR-YC1059 | Human anti-RYR3 T cell receptor (FB3), pCDTCR1 | Human | FB3 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector | |
TCR-YC1060 | Human anti-RYR3 T cell receptor (GC12), pCDTCR1 | Human | GC12 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector | |
TCR-YC1061 | Human anti-RYR3 T cell receptor (GD12), pCDTCR1 | Human | GD12 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector | |
TCR-YC1062 | Human anti-RYR3 T cell receptor (KC12), pCDTCR1 | Human | KC12 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector | |
TCR-YC1063 | Human anti-RYR3 T cell receptor (MB12), pCDTCR1 | Human | MB12 | Human | VLNYFEPYL | HLA-A2 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION